TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00842673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: 30 mg; administered once/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: 90 mg; administered once/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: 180 mg; administered once/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match ST101 tablets
Study: NCT02783924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Vitamin D preparation
Study: NCT03635749

Intervention type: DRUG
Group type: OTHER
Intervention: Immediate high-intensity statin
Description: Day 1 - 21：Atorvastatin calcium 80mg/day~Day 22 - 90：Atorvastatin calcium 40mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate high-intensity statin
Description: Day 1 - 21：Atorvastatin calcium 80mg/day~Day 22 - 90：Atorvastatin calcium 40mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delayed high-intensity statin
Description: Day 1 - 3：Atorvastatin calcium placebo~Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo~Day 22 - 90：Atorvastatin calcium 40mg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Delayed high-intensity statin
Description: Day 1 - 3：Atorvastatin calcium placebo~Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo~Day 22 - 90：Atorvastatin calcium 40mg/day
Study: NCT02954614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active play in after school programs (ASP)
Description: * A 15 hour training-program for ASP-staff aimed to increase active play and physical activity among children in ASPs. The program includes lectures, guided discussions and practical tasks focusing on increasing the staffs competence in how to support active play and PA among all children in the ASP~* A 8 hour course for local physiotherapists enabling them to guide ASP-staff during parts of the intervention period
Study: NCT02783924

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03623503

Intervention type: OTHER
Intervention: Observational study

Intervention type: OTHER
Intervention: Observational study
Study: NCT03740035

Intervention type: DEVICE
Intervention: eHealth for Sedentary Behavior
Description: Prostate cancer patients will be testing the usability and acceptability of the eHealth web app for sedentary behavior
Study: NCT01023815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
Study: NCT02316171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVA21
Description: CAVATAK is a purified preparation of CVA21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVA21
Description: CAVATAK is a purified preparation of CVA21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Chemotherapy
Study: NCT00799435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks
Study: NCT04354324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radioiodine
Description: The test group: low dosage (30mci). The control group: high dosage (100mci).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioiodine
Description: The test group: low dosage (30mci). The control group: high dosage (100mci).
Study: NCT00479713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator : rosuvastatin calcium
Description: rosuvastatin 10mg. The treatment duration will be 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo (unspecified)
Description: rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
Study: NCT03216408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuronox

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Study: NCT02872246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987516
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 Control
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Study: NCT05332847

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POC-US
Description: Point Of Care Ultrasonography (POCUS) is a rapidly evolving bedside modality in which ultrasonography is utilized as a part of the bedside physical examination and the patients' clinical assessment
Study: NCT04503265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXI-5001:Dose Escalation Phase I
Description: Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXI-5001:Dose Expansion Phase II
Description: Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
Study: NCT00191334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
Study: NCT02173106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid & Cyclosporin
Description: oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
Study: NCT02747810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NewTENS Design
Description: This device functions the same as the FDA approved TENS unit, but provides a small, inexpensive unit that will be easy for a child to use. The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will also be instructed how to use the stimulator and where to attach the electrodes on the foot at the beginning of the study. The investigator will provide the stimulator and electrodes. The subjects will be asked to wear socks to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a MINIMUM of 60 minutes in the evening prior to bedtime at home for two weeks. They will be encouraged to use the stimulator for more time than the minimum as long as they accurately record the total duration.
Study: NCT04466852

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: telemedicine-guided consultation
Description: Educational material is provided as short audiovisual films for understanding heart failure condition and management, how medicines work and their side effects, general advise on diets, exercise and importance of refraining from toxic exposure (smoke, alcohol, narcotics and damaging illegal medicines). Additionally, the patient (eventually assisted by their relatives and caregivers) can use this platform for learning basic important warning signs or cardiac decompensation based on feedback on recording regular measurements (weight, blood pressure and pulse and blood tests when needed) and symptoms. The cardiologist guides the patient and their Family/Basic doctors on the need for follow-up based on the parameters recorded. Videoconsultations with participation of the cardiologist, the Family/Basic doctor and the patient and relatives are used on demand.
Study: NCT06725251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Dyads will take part in a portrait-making project utilizing a collage approach. Each participant (i.e. dementia diagnosed individuals and care partners) will be instructed to create a portrait of him/herself. Participants will be provided with a sample portrait as well as bins of materials. \]The intervention will be administered for 1 ½ hours weekly, at the same day/time, for 4 consecutive weeks.
Study: NCT06726317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early palliative care integration
Description: The early palliative care intervention package was developed following the guidelines provided by the UK Medical Research Council for the development of complex interventions. The early palliative care intervention for patients with oral cancer had six components: 1) providing information, 2) addressing acute and functional issues, 3) nutritional care, 4) psychological support, 5) mindfulness therapy, and 6) coordination of the financial allowance. The package was formulated by triangulating literature review findings and several independent studies: a case-control study; in-depth interviews with experts in the field of oncology and palliative care in Sri Lanka; key-informant interviews with patients with oral cancer and their caregivers; and an observation study at the National Cancer Institute Sri Lanka- Apeksha Hospital). The intervention package was finalized through a
Study: NCT03288571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton Jelly Mesenchymal stem cells
Description: Wharton Jelly Mesenchymal stem cells will be injected in the renal parenchyma
Study: NCT03229083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carevive software
Description: In this study, Carevive will deliver a link to subjects so that an online survey can be completed. The survey will occur weekly for the first 12 weeks of the study and will be spaced out to every other week thereafter. The questions will mostly focus on side effects from their cancer therapy, as well as a few questions about drug compliance and healthcare utilization. After completion of the survey, the subject will be given a care plan with at home self-management options for drug-related toxicities.
Study: NCT01023815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednison (continuous steroids)
Description: continuous steroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednison (continuous steroids)
Description: continuous steroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednison (continuous steroids)
Description: continuous steroids
Study: NCT00762073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral suspension matching budesonide
Study: NCT04383652

Intervention type: OTHER
Intervention: Biological sample and clinical data collection
Description: Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.

Intervention type: OTHER
Intervention: Biological sample and clinical data collection
Description: Plasma and serum will be collected at day 0, day 7, day 14, 1 month and 4 months post diagnosis. Clinical data related to COVID-19 diagnosis, symptoms, and outcomes will be collected.
Study: NCT00209235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive and psychosocial testing
Description: Neurocognitive and psychosocial testing
Study: NCT04272411

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham SCS stimulation
Description: Sham SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tonic SCS stimulation
Description: Tonic SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Burst SCS Stimulation
Description: Burst SCS stimulation via implanted neuromodulation device for 45 min during the steady state of a hyperinsulinemic euglycemic clamp.
Study: NCT02801149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wrist Magnetic Resonance Imaging (MRI)
Description: Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
Study: NCT05564507

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TEE simulation-based training
Description: All participants of the TEE simulation-based training group received:~1. a traditional didactic training using e-learning with a national free-access online course;~2. two teaching sessions using a TEE simulator for 2 hours per session. The simulation session will involve standardized initial teaching of normal cardiac, including anatomy of mitral valve with some mitral regurgitation cases, aortic valve, tricuspid valve, interatrial septum, and left atrial appendage, and demonstration of image acquisition by the teacher (time duration: 30 min). The duration of each session was 2 h with a 6:1 student to instructor ratio. Each subject had a dedicated 20 min of hands-on to manipulate the probe and undertake a sequential TEE examination under the supervision of the teacher. Other participants could watch their colleagues working on the TEE simulator.
Study: NCT04011891

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Partial Nephrectomy
Description: Robotic partial nephrectomy using da Vinci robot.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Partial Nephrectomy
Description: Standard open partial nephrectomy
Study: NCT03447587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Each subject will be treated with predefined acupoints including bilateral Ear-Shenmen, Touwei (ST8), Sishencong (EX-HN1), and unilateral Yintang (EXHN3) and Baihui (GV20) on the head (total 8 needles). Subject's current symptoms will be ascertained using a Traditional Chinese Medicine symptom checklist and eight additional acupoints will therefore be selected and needled based on their clinical judgements. The acupuncture treatment will consistent of two sessions per week (30 minutes) for 4 consecutive weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupuncture
Description: Subjects will be treated at 1 cm posteriorly and laterally adjacent to the same acupoints as the traditional acupuncture group using validated non-invasive sham needles. Subjects will also be assessed with Traditional Chinese Medicine checklist. The acupuncturist, setting, treatment frequency, and duration of the treatment course will be the same as in the traditional acupuncture group.
Study: NCT03685916

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Plain rice with plain water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cumin Rice
Description: Cumin rice with plain water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cumin Drink
Description: Cumin drink with plain rice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cornsilk Rice (Low dose)
Description: Low dose cornsilk rice with plain water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cornsilk Rice (High dose)
Description: High dose cornsilk rice with plain water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cornsilk Drink (Low dose)
Description: Low dose cornsilk drink with plain rice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cornsilk Drink (High dose)
Description: High dose cornsilk drink with plain rice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tamarind Rice
Description: Tamarind rice with plain water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tamarind Drink
Description: Tamarind drink with plain rice
Study: NCT01582776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and GA101
Description: 1000mg of GA101 on D8, D15 and D22of cycle 1 and on D1 of cycles 2 to 6. Oral lenalidomide once daily at 10/15/20/25mg (phase I part) or at recommended dose (phase II part) on days 1 to 21 of a 28-day cycle for the first cycle and on days 2 to 22 of a 28-day cycle for cycles 2 to 6.
Study: NCT04108897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Topical
Description: 1% topical ivermectin.
Study: NCT04037280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Four type of exercises will be delivered to patients. These exercises differ for posology and typology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Four type of exercises will be delivered to patients. These exercises differ for posology and typology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Four type of exercises will be delivered to patients. These exercises differ for posology and typology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Four type of exercises will be delivered to patients. These exercises differ for posology and typology.
Study: NCT01715961

Intervention type: PROCEDURE
Group type: OTHER
Intervention: anthropometric measurement
Description: To attest the muscular strength: hand grip test, balance test, up and go test
Study: NCT02143128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Efficacy Safety Score
Description: Evaluation using the score for postoperative patients
Study: NCT00794274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-100004
Description: After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
Study: NCT05085678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Co'moon (online website to support women with AET)
Description: The tool contains three parts:~1. e-learning based on the brochure on adjuvant endocrine therapy (AET) in the University Hospital Leuven,~2. serious game where patients are confronted with scenes of their daily life and motivational guidelines to stimulate their self-management,~3. a patient-reported-outcome questionnaire (PROMs), reported in the patient medical file.~The tool is designed to stimulate patients self-management of their menopausal AET-related complaints and to discuss them with their health care professionals .
Study: NCT02143128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Numeric Rating Scale
Description: Patients assessed for postoperative pain using VNRS (0-10)